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• Proteomic analysis of synapses isolated from Alzheimer’s disease and control subject 
brains identifies over 5,500 proteins in human synapses. 
• In silico analysis reveals region-specific decreases in proteins involved in synaptic and 
mitochondrial function and increases in proteins involved in neuroimmune signaling 
and intracellular signaling in AD. 
• The apolipoprotein E4 risk gene is associated with exacerbated changes in synaptic 
proteins in AD. 
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Abstract 
Degeneration of synapses in Alzheimer’s disease (AD) strongly correlates with cognitive 
decline, and synaptic pathology contributes to disease pathophysiology. We recently observed 
that the strongest genetic risk factor for sporadic AD, apolipoprotein E epsilon 4 (APOE4), is 
associated with exacerbated synapse loss and synaptic accumulation of oligomeric amyloid 
beta in human AD brain.  To begin to understand the molecular cascades involved in synapse 
loss in AD and how this is mediated by APOE, and to generate a resource of knowledge of 
changes in the synaptic proteome in AD, we conducted a proteomic screen and systematic in 
silico analysis of synaptoneurosome preparations from temporal and occipital cortices of 
human AD and control subjects with known APOE gene status.  We examined brain tissue 
from 33 subjects (7-10 per group).  We pooled tissue from all subjects in each group for 
unbiased proteomic analyses followed by validation with individual case samples. Our analysis 
identified over 5,500 proteins in human synaptoneurosomes and highlighted disease, brain 
region, and APOE-associated changes in multiple molecular pathways including a decreased 
abundance in AD of proteins important for synaptic and mitochondrial function and an 





Dementia poses one of the biggest societal challenges of the 21st century. Over 50 million 
people are living with dementia worldwide, it costs over $800 billion per year to care for 
them, and there are currently no disease modifying treatments [54].  One of the barriers to 
developing effective therapies for Alzheimer’s disease, the most common cause of dementia, 
lies in the lack of a comprehensive understanding of the brain changes that cause 
neurodegeneration. In particular, a key knowledge gap is not yet understanding how genetic 
risk factors contribute to disease pathogenesis [35]. Extracellular amyloid beta (Ab) plaques, 
intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, and severe 
brain atrophy are the major neuropathological hallmarks of AD [45]. There are many genetic 
risk factors for developing sporadic AD, the strongest of which is inheritance of the 
apolipoprotein E epsilon 4 allele (APOE4).  Inheritance of one copy of APOE4 is associated 
with a 3 fold increase in disease risk and inheritance of two copies with an over 10 fold 
increased risk [9].  In addition to its known roles in Ab production and clearance, we and 
others have observed that apoE protein accumulates in synapses [3, 22, 27, 50], which is 
important as synapse loss is  the strongest pathological correlate with cognitive decline in AD 
[13, 48, 51]. ApoE4 causes more synaptic loss around plaques when expressed in mouse 
models of familial AD [22]. Using high resolution imaging in human post-mortem brain 
tissue, we similarly observed exacerbated synapse loss in APOE4 carriers and further that 
apoE4 is associated with more accumulation of oligomeric Aß at synapses [24, 27]. More 
recent data implicates APOE4 in tau mediated neurodegeneration [47] and also inflammatory 
TREM2 mediated microglial phenotypes [28], which may be important for synapse 
degeneration [52]. Further highlighting the importance of APOE to AD progression, the 
Christchurch mutation in APOE3 was recently observed to be associated with delayed disease 
onset in a person with a familial AD mutation in presenilin 1 [2] .  
 
Recent data from postnatal human brain samples shows that proteomic datasets can reveal 
differences in proteins that are not observed in RNA expression data, arguing the importance 
of building strong resource datasets at the level of protein in human diseases [7]. Thus far there 
have been several proteomic studies of human AD brain tissue (supplemental table 1), but a 
comprehensive dataset on human synaptic proteins examining the effects of APOE genotype 
in AD remains unavailable.  
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In order to further our understanding of how APOE may be influencing synaptic vulnerability 
in AD, we have performed a comprehensive proteomic study of human post-mortem brain 
tissue through a series of molecular comparisons allowing us to assess the relative contribution 
of both regional vulnerability and APOE variants to AD pathogenesis. Although our study is 
in postmortem tissue which has inherent limitations including looking at a snapshot of the end 
stage of the disease, the inclusion of a less affected brain region allows some novel insight into 
changes that may be occurring in synapses earlier in the degenerative process. We provide a 
unique proteomic resource identifying over 5,500 proteins in human synaptoneurosome 
preparations.  These preparations enrich remaining synapses in the brain and unlike 
examination of total homogenates allow specific examination of change in synaptic proteins 
without the confound of synapse loss [49].  Additionally, we highlight multiple proteins and 
molecular pathways that are modified in AD with brain region and APOE genotype status.  In 
silico analysis reveals that proteins involved in glutamatergic synaptic signalling and synaptic 
plasticity are decreased in AD with temporal cortex (which has high levels of pathology) being 
more severely affected than occipital cortex (which has lower levels of pathology) and APOE4 
carriers more affected than APOE3 carriers.  Alterations in glial proteins important for 
neuroimmune signalling were also detected using in silico analysis, and further investigation 
revealed a host of proteins involved in the complement cascade are not only found in human 
synapses but are increased in AD compared to control brain.  In addition to providing a resource 
for the field, our data support the hypothesis that APOE genotype plays an important role in 
synaptic dysfunction and degeneration in AD.   The proteins and pathways identified as altered 
in this study can in future be investigated in more detail for their potential as therapeutic 
intervention points to delay or prevent synaptic alterations and the consequential symptoms 




Use of human tissue for post-mortem studies has been reviewed and approved by the 
Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics 
committee, AMREC (ACCORD is the Academic and Clinical Central Office for Research 
and Development, a joint office of the University of Edinburgh and NHS Lothian, approval 
number 15-HV-016). The Edinburgh Brain Bank is a Medical Research Council funded 
facility with research ethics committee (REC) approval (16/ES/0084).   
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Fresh frozen brain tissue for proteomics and paraffin embedded tissue for examination of 
pathology was provided from superior temporal gyrus (BA41/42) and primary visual cortex 
(BA17). Tissue was requested from clinically diagnosed AD and control subjects.  All cases 
were examined by a neuropathologist, and after the proteomics results were returned, it was 
noted that one of the AD cases was neuropathologically classified as frotntotemporal 
dementia with tau-associated corticobasal degeneration (table 1).    The pooled design of the 
study precludes exclusion of this case post-hoc but also reduces inter-individual 
heterogeneity [25, 36].  However, pooled analyses on difficult sample types such as serum 
have also been reported to be associated with false positive and false negative results [37]. 
While this has not been a problem in any of our previous analyses of synaptically enriched 
fractions, it does highlight the need for validation of results.  
 
Table 1: Subject characteristics. We observe the expected decrease in brain weight in AD (2-
way ANOVA effect of disease F(1,29)=9.018, P=0.0055, no significant effect of genotype).  
The control APOE3/4 group is not age matched.  Age is significantly different in AD vs control 
(2-way ANOVA effect of disease F (1, 29) = 17.4, P=0.0003, * Tukey’s multiple comparison 
test control APOE3/4 significantly different from AD APOE3/4 age p=0.002).  There are no 
differences in age between AD APOE3/4 and AD APOE4/4 cases. There are no significant 




DNA was extracted from ~25mg of cerebellum for each case using the QIAamp DNA mini 
kit (Qiagen, Hilden, Germany), which was used as per the manufacturer’s instructions. 
Polymerase chain reaction (PCR) was performed on the extracted DNA.  10µl of 2x Master 
mix (Promega, Madison, WI) was combined with 1µl of primer stock (20µM forward primer, 
20µM reverse primer), 2µl of DMSO (Sigma-Aldrich, St Louis, MO), 6µl ddH2O and 1µl of 
isolated DNA. The forward primer was 5’taagcttggcacggctgtccaagg3’ and the reverse primer 
5’acagaattcgccccggcctggtacactgcc3’ (Figure 2.2A). APOE e2, APOE e3, and APOE e4 
plasmids (generously donated by Dr E Hudry) were also amplified by PCR to use at as 
reference and were treated in the same way as unknown samples throughout.  PCR product 
was digested using the restriction endonuclease HhaI (New England Biolabs, Ipswich, MA). 
For this 0.5µl of enzyme, 2.5µl of 10x CutSmart buffer (New England Biolabs, Ipswich, MA) 
and 2µl of ddH2O were added to each PCR reaction tube to give a total volume of 25µl. The 
final volume contains 50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium 
Acetate, and 100 µg/ml BSA as a result of the CutSmart buffer and 10 units of HhaI.  After 
digestion incubation 5µl of 6x Blue Loading dye (Promega, Madison, WI) containing 0.4% 
orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10mM Tris-
HCl (pH 7.5) and 50mM EDTA (pH 8.0) was added to the the reaction tube. 14µl of this 
mixture was then loaded onto precast 15 well Novex TBE 20% gel (Thermo Fisher Scientific, 
Waltham, MA) using a 25µL Hamilton Syringe. The DNA were then separated by size using 
electrophoresis for 2 hours at 200V. The gels were run in an XCell SureLock™ Mini-Cell 
(Invitrogen, Carlsbad, CA) using Novex TBE running buffer (Thermo Fisher Scientific, 
Waltham, MA). Bands were stained with either 2µg/ml ethidium bromide (Sigma-Aldrich, St 
Louis, MO) or SYBR safe DNA Gel Stain (Thermo Fisher Scientific, Waltham, MA) and 
visualized with an ultraviolet gel imaging system (Syngene, Cambridge, UK). 
 
Amyloid beta and Tau staining in human cortical sections 
Tissue sections were stained for amyloid beta and tau according to a previous study [17]. 
Briefly, fresh post-mortem tissue blocks were fixed in formalin and dehydrated in an ascending 
alcohol series. Three paraffin waxing stages were performed and 4µm thick tissue sections 
were cut on a Leica microtome and collected on glass slides. Immunohistochemistry for 
amyloid beta (BA4, M087201-2, Agilent) and pTau (AT8, MN1020, Thermo) was performed 
using the Novolink Polymer detection system and visualized using DAB as chromogen. Images 
 7 




Brain homogenates and synaptic fractions were prepared as described in Tai et al. 2012 [49]. 
In brief, ~300mg of cortical tissue was homogenized on ice in homogenization buffer (25 mM 
HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, protease inhibitors 
(roche complete mini), phosphatase inhibitors (Millipore, 524629)). The homogenate was 
filtered through 2 layers of 80µm nylon filter (Millipore, NY8002500) and saved as crude 
homogenate. The crude homogenate was further filtered through a 5 µm filter (Millipore, 
SLSV025NB) and centrifuged at 1000g for 5 min. The pellet was washed once, then the 
supernatant was removed and the pellet was resuspended in in label-free buffer [100 mM Tris-
HCl (pH7.6) 4% (w/v) SDS] containing 1% protease cocktail inhibitor (Thermo Fisher, UK). 
Homogenates were centrifuged at 20,000 x g for 20 minutes at 4°C with the soluble fraction of 
each sample transferred to Lo-Bind tubes (Sigma Aldrich). Protein determination using the 
Bicinchoninic acid assay (Pierce, UK) was carried out according to manufacturer’s guidelines. 
 
Electron microscopy  
Synaptoneurosome pellets were fixed in 4% paraformaldehyde/ 2% glutaraldehyde in PB for 
48 hours at 4° C.  Pellets were then post fixed in 1% osmium tetroxide for 30 min, rinsed, and 
dehydrated in increasing concentrations of ethanol with uranyl acetate 1% in the 70% ethanol 
step for 1 hour.  After 100% ethanol, pellets were rinsed in propylene oxide then embedded in 
Durcupan resin per manufacterers instructions.  70nm sections were cut on an Ultracut 
microtome (Leica) with a histo jumbo diamond knife (Diatome) and moutned on 300 mesh 
copper EM grids (Electron microscopy sciences).  Sections were stained with lead citrate in a 
CO2 free environment for 2 min, rinsed in boiled double distilled water, and imaged on a JOEL 
JEM-1400 transmission electron microscope at an effective magnification of 25,000x-50,000x. 
 
SDS-PAGE and western blotting 
SDS-PAGE and western blotting were performed as described previously [19]. Briefly, 5µg of 
protein from synaptoneurosome fractions and molecular weight marker (Li-Cor, Cambridge, 
UK) was loaded onto NuPAGE 4-12% Bis-Tris precast polyacrylamide 15 well gels 
(Invitrogen, Paisley, UK). Proteins were transferred to polyvinylidene fluoride (PDVF) 
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membranes and blocked using Odyssey Blocking buffer (927-40,000, Li-Cor) diluted 1:1 in 
PBS. Primary antibodies were incubated overnight in blocking buffer and proteins were 
detected on an Odyssey system using 680 and 800 IR dye secondary antibodies diluted 1:10000 
in blocking buffer (table 2 shows antibodies used in western blots). Total protein stains were 
performed with Instant Blue total protein stain per manufacturer instructions (Expedeon). 
 
Protein Manufacturer Catalogue Validation for WB (from manufacturers 
website) 
RRID 
Actin Abcam AB 8226 Cell lysates from HeLa, Jurkat, A431, HEK293, NIH 
3T3, PC12 cells. 
AB_306371 
Alpha synuclein Santa Cruz Sc-7011-R SH-SY5Y cell lysate, α-synuclein expression in mouse 
and rat brain tissue extracts. 
AB_2192953 
Annexin V Abcam AB 54775 ANXA5 expression in Hela, 293T cell line, 
pentoxifylline cell treatment. 
AB_940268 
Beta Tubulin  Abcam AB 18207 HAP1 cell lysate; mouse brain and hippocampus lysates; 
rat brain lysate; human brain lysate. Knock out cell lines 
studies. 
AB_444319 




GFAP Dako/Agilent Z033429-2 
 
antibody solid-phase absorbed with human and cow 
serum proteins. One distinct precipitate (GFAP) with 




Histone H3 Abcam Ab 1791 HeLa, Drosophila embryo nuclear extract, 




NMDANR2B BD Biosciences 610416 Rat NMDA receptors AB_397796 
 
 
PSD95 Abcam AB 18258 Mouse and rat brain lysates. PSD95 knockout mouse and 
immunoprecipitation. 
AB_444362 
SNAP25 Abcam AB 53723 RAW264.7 cell extracts and blocking peptides. AB_882623 
SOD2 novusbio NB100-1992 Rat brain tissue extract. AB_535862 




TMEM97 Atlas Antibodies HPA044795 Recombinant expression validation using target protein 
overexpression. 
AB_10959306 
WB: Western blot. RRID: Research Resource Identifiers. 




Pools containing equal amounts of protein (25 µg per case) were prepared of each of the 8 
groups (control APOE3/3 BA41/42, control APOE3/3 BA17, control APOE3/4 BA41/42, 
control APOE3/4 BA17, AD APOE3/3 BA41/42, AD APOE3/3 BA17, AD APOE3/4 
BA41/42, AD APOE3/4 BA17).  Preparation of the samples, quantification, and bioinformatics 
was carried out according to standardized protocols [15, 25, 32].  
 
Samples were lysed in 4%SDS + 100mM tris prior to protein estimation by microBCA. Each 
sample was then reduced with 100 mM DTT and samples then processed using the FASP 
protocol [56] with some modifications. Samples were initially diluted 1:10 into 8M Urea and 
buffer exchanged to remove the SDS and tris buffer, filters were then washed 3 times with 
100 mM Tris-HCL pH 8 then another 3 times with 100 mM triethyl ammonium bicarbonate 
(TEAB). Proteins on the filters are then digested twice at 30oc with trypsin (2 x 1ug), first 
overnight and then for another 6h in a final volume of 200 µl prior to addition of 200ul of 
500mM NaCl. Samples were then desalted using a SPE cartridge (Empore-C18, Agilent 
Technologies, 7mm/3ml) and the peptides dried in a speedvac (Savant). 
  
Desalted tryptic peptides (25µg each sample) were then dissolved in 100 µl 100 mM TEAB. 
The different 8 TMT labels were dissolved in 41µL of anhydrous acetonitrile, and each label 
then added to a different sample. The mixtures were incubated for 1 hour at room 
temperature and the labelling reaction was then quenched by adding 8µL of 5% 
hydroxylamine. Following labelling with TMT, samples were mixed, desalted using a SPE 
cartridge (Empore-C18, Agilent Technologies, 7mm/3ml) and the peptides dried in a 
speedvac (Savant). Samples were then dissolved in 200 µL ammonium formate (10 mM, pH 
10) and peptides fractionated using High pH RP HPLC.   A C18 Column from Waters 
(XBridge peptide BEH, 130Å, 3.5 µm 2.1 X 150 mm, Ireland) with a guard column 
(XBridge, C18, 3.5 µm, 2.1X10mm, Waters) are used  on a Ultimate 3000 HPLC (Thermo-
Scientific). Buffers A and B used for fractionation consists,  respectively of 10 mM 
ammonium formate in milliQ water and 10 mM ammonium formate with 90% acetonitrile, 
both buffers were adjusted to pH 10 with ammonia.  Fractions were collected using a WPS-
3000FC auto-sampler (Thermo-Scientific) at 1 min intervals. Column and guard column were 
equilibrated with 2% buffer B for 20 min at a constant flow rate of 0.2 ml/min. Samples (175 
µl) were loaded onto the column at 0.2 ml/min. Peptides were eluted from the column with a 
gradient of 2% buffer B to 5%B in 6 min then from 5% B to 60% B in 50 min. The column is 
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washed for 16 min at 100% buffer B and equilibrated at 2% buffer B for 20 min as mentioned 
above.   The fraction collection started 1 min after injection and stopped after 80 min (total of 
80 fractions, 200 µl each). The total number of fractions concatenated was set to 20 by non-
contiguous pooling and the content of the fractions dried and resuspended in 50 µl of 1% 
formic acid prior to analysis by nLC-MS/MS. 
  
Analysis of peptides was performed using a Q-Exactive-HF (Thermo Scientific) mass 
spectrometer coupled with a UltiMate 3000 RSLCnano (Thermo Scientific) UHPLC system. 
nLC buffers were as follows:  buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q 
water (v/v)) and buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v). 
Aliquots of 15 µL of each sample (50ul in total) were loaded at 5 µL/min onto a trap column 
(100 µm × 2 cm, PepMap nanoViper C18 column, 5 µm, 100 Å, Thermo Scientific) 
equilibrated in 98% buffer A. The trap column was washed for 6 min at the same flow rate 
and then the trap column was switched in-line with a Thermo Scientific, resolving C18 
column (75 µm × 50 cm, PepMap RSLC C18 column, 2 µm, 100 Å). The peptides were 
eluted from the column at a constant flow rate of 300 nl/min with a linear gradient from 95% 
buffer A to 40% buffer B in 122 min, and then to 98% buffer B by 132 min. The column was 
then washed with 95% buffer B for 15 min and re-equilibrated in 98% buffer A for 32 min. 
Q-Exactive HF was used in data dependent mode. A scan cycle comprised MS1 scan (m/z 
range from 335-1800, with a maximum ion injection time of 50 ms, a resolution of 120 000 
and automatic gain control (AGC) value of 3x106) followed by 15 sequential dependant MS2 
scans (with an isolation window set to 0.7 Da, resolution at 60000, maximum ion injection 
time at 200 ms and AGC 1x105. To ensure mass accuracy, the mass spectrometer was 
calibrated on the first day that the runs are performed. 
 
The raw mass spectrometric data files obtained for each experiment were collated into a 
single quantitated dataset using MaxQuant 1.6.0.16 [10] and Andromeda search engine 
software [11] with enzyme specificity set to trypsin. Other parameters used were: (i) variable 
modifications, deamidation (NQ), oxidation (M), protein N-acetylation, gln-pyro-glu; (ii) 
fixed modifications, carbamidomethylation (C); (iii) database: uniprot-human_Sept2017 
database; (iv) Reporter ion MS2 – TMT labels: TMT8plex_Nter and TMT 8plex-Lys ; (v) 
MS/MS tolerance: FTMS- 10ppm, ITMS- 0.02 Da; (vi) maximum peptide length, 6; (vii) 
maximum missed cleavages, 2; (viii) maximum of labelled amino acids, 3; and (ix) false 
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discovery rate, 1%. Peptide ratios were calculated using ‘Reporter Intensity’ Data that was 
normalised using 1/median ratio value for each identified protein group per labelled sample. 
 
In silico analyses 
Filtered data was utilised for all bioinformatics statistical analyses and filtered by the following 
excluding proteins identified by only 1 peptide. For some analyses we filtered for proteins that 
demonstrated a ±>20% change between APOE3/4 BA41/42 AD and control subjects.  The 
Database for Annotation Visualization and Integrated Discovery (DAVID) was used to test 
whether synaptic protein sets were enriched in the samples [21].  To obtain further insight into 
potential pathways changed in AD synapses, Ingenuity Pathway Analysis (IPA, Ingenuity 
Systems) was used as previously described [15, 32, 55] with the interaction data limited as 
follows: direct and indirect interactions; experimentally observed data only; 35 molecules per 
network; 10 networks per dataset. Prediction activation scores (z- scores) were calculated in 
IPA. Expression clustering was performed in Biolayout Express 3D software by applying 
Markov clustering algorithms to raw proteomic data (MCL 19 2.2) as previously described in 
[32]. All graphs were clustered using Pearson correlation r=0.96. 
 
Data sharing 
Unfiltered proteomics data is included as supplemental table 5. The mass spectrometry 
proteomics data have also been deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository [39], with the dataset identifier PXD013753.  DAVID analysis is 
provided in supplemental table 2. The full IPA analysis from Figure 3 is in supplemental 
table 3. Complement proteins identified are in supplemental table 4. Filtered proteomics data 
used for IPA analysis in figure 3 is provided in supplemental table 6.  
 
Results 
Development of a human post-mortem synaptic reference proteome 
To better understand the changes in synapses that may contribute to disease pathogenesis in 
AD and how the genetic risk factor APOE contributes to synaptic vulnerability, we conducted 
a proteomic study of human post-mortem brain tissue. Using immunohistochemistry, 
proteomics, and western blots, we examined two brain regions, superior temporal gyrus 
(BA41/42) which has a severe pathological burden and primary visual cortex (BA17) which is 
less severely affected even at the end stages of disease (Figure 1a & b)[45]. With this study 
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design incorporating disease, brain region, and APOE genotype, it is possible to design a series 
of comparisons which will enable the interrogation of complex proteomic comparisons in a 
biologically meaningful way (Figure 1c). Through the MRC Edinburgh sudden death brain 
bank, we were able to access samples from 33 brain tissue donors whose condition and 
underlying genetics were amenable to this particular investigation. Details of subjects in the 
study can be found in Table 1.  
 
 
Fig. 1: Increased pathology in temporal compared to occipital cortex and in APOE4 
compared to APOE3 carriers.  Representative images of immunohistochemistry for amyloid 
beta (a) tau (b) (brown) and Hematoxylin and Eosin counterstain for cells (blue) highlight the 
higher pathological load in APOE4 carriers than APOE3 carriers and more pathology in 
superior temporal gyrus (BA41/42) compared to primary visual cortex (BA17). For analysis, 
we examined ratios of AD vs control samples in the 2 brain regions and with APOE3/3 or 
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APOE3/4 genotype to examine how the synaptic proteome changes with differential pathology 
(c). Scale bars represent 200µm (a) 50µm (b). 
 
 
Synaptic fractions were prepared and quality control for post-mortem protein degradation were 
confirmed as previously described[15, 25, 32] (Fig. 2).  Enrichment of synaptic proteins and 
exclusion of nuclear protein were confirmed by western blot (Fig. 2a). Any synaptoneurosome 
preparations containing nuclear histone protein were discarded and fresh preparations made 
from the same case.  Protein degradation was assessed using comparison of total protein stains 
(Fig 2b-d) and using the “HUSPIR” ratio which examines NMDAR2B degradation that occurs 
postmortem [6] (Supplementary Fig 2).  The HUSPIR ratio significantly correlated with RNA 
integrity number (p=0.009, R2=0.215, linear regression analysis) and brain pH (p=0.023, 
R2=0.184, linear regression analysis) but not at all with post-mortem interval.  RIN and pH are 
routinely collected for all brain bank samples and used as a proxy for tissue integrity. Here we 
confirm that protein degradation correlates better with these markers than with post-mortem 
interval highlighting the importance of tissue handling in maintaining protein integrity.  
Electron microcopy conducted on synaptoneurosome pellets (Fig. 2e) confirms preservation of 
pre and postsynaptic terminals in pairs with our synaptoneurosome preparation as we had 
previously observed [49]. We observe clear post synaptic densities, presynaptic vesicles, and 
synaptic mitochondria. 
 
Having confirmed that the extracted protein is of appropriate quality, we then applied a 
comprehensive workflow to enable us to assess (at the protein level) the relative contribution 
of both regional vulnerability and APOE variants as a risk factors to AD pathogenesis (Figure 
1c, Supplemental figure 1) [15, 32]. We performed a complex 8-plex TMT LC-MS/MS 
analysis. Representative pools based on the outlined groupings were generated from these 
synaptic protein extracts. By pooling individual samples according to APOE genotype and 
cortical area, we were able to reduce potential noise in the system generated through inter 
individual differences, subtle post mortem handling differences and/or sample isolation [16]. 
Thus, 25 µg of each of the 33 subjects were pooled according to disease status, APOE genotype 
(3/3 or 3/4) and brain region (BA41/42 or BA17). The inclusion of an equivalent proportion of 
each protein isolate into a readily comparable pool allowed the generation of a molecular 
fingerprint representative of each condition and enables subsequent analysis of individual 
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patient variability in the resulting validatory work (as a deviation from the population signal, 





Figure 2: Enrichment and integrity analysis of synaptic protein preparations a) A 
representative western blot from 3 cases shows the enrichment of synaptic proteins and 
exclusions of histones from the synaptoneurosome preparation (P) compared to crude 
homogenate (H) protein from that sample. Blots were probed for PSD95, synaptophysin, 
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histone and GAPDH.  b) Total protein analysis (TPA) was also used to determine whether any 
samples showed evidence of protein degradation. Boxes in panel (B) indicate the molecular 
weight ranges analysed for total protein stain. Quantification reveals no difference in total 
protein in BA17 (c) or BA41/42 (d) samples (One way ANOVAs, p>0.05). Transmission 
electron microscopy confirms that synaptoneurosome preparations contain paired pre and post 
synaptic terminals as expected (e).  We observe clear electron dense postsynaptic densities 
(arrows), presynaptic vesicles (arrowheads), presynaptic mitochondria (m) and small processes 
associated with synapses (*).  Scale bar represents 500 nm. 
Following detection on the mass spectrometer, quantitation of the dataset using MaxQuant 
[10]and Andromeda search engine software [11] we identified 7148 protein identifications 
(IDs) in total. These 7148 identified proteins were then filtered to include only proteins 
identified by 2 or more unique peptides (Figure 3c).  This yielded 5678 proteins. A DAVID 
enrichment analysis of this filtered list of proteins served to further confirmed enrichment of 
the samples for synaptic material (Supplemental table 2). 
 
Supplemental table 2: DAVID Analysis confirms enrichment of synaptic proteins.  
 
Having confirmed that the proteomic data is likely to be representative of the synaptically 
enriched starting material we then filtered to include only those demonstrating differential 
abundance of equal to or greater twenty percent  (up or down regulated) in the comparison AD 
vs. ctrl in BA41/42 in APOE4 carriers (Fig. 3). After applying these further two data filtering 
steps we obtained a set of 1532 protein IDs identified with high confidence and meeting our 
differential abundance criteria.  
 
In order to validate the proteomics data, we selected a subset of 9 proteins for western blot 
analysis in BA41/42 whose levels should be increased or decreased just past our magnitude of 
change cutoff as this will be more indicative of the sensitivity of the MS than highly up or 
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downregulated proteins.  We also selected a protein whose levels was unchanged to use as an 
internal control  (Fig 3, supplementary figure 3) [44].  All of the proteins we chose for 
validation by western blot went in the direction indicated by the proteomics results and the 
ratios of AD/non-demented control levels in western blots significantly correlated with those 
found with proteomics (Pearson’s correlation p=0.03, details in Figure 3).  
 
Fig. 3: Synaptic proteomes are altered by AD and APOE genotype a) Heat map with 
hierarchical clustering demonstrates the differential abundance of the 5678 individual 
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proteins across “spared” and “vulnerable” brain regions and with APOE genotype. The ratios 
compare AD to control in each condition. b) Stacked bar chart demonstrates there is a direct 
correlation between the number of proteins that are differentially expressed, by 20% or more 
(up or down regulation), with the “vulnerability status’ of the synapses as determined by both 
genotype and brain region. c) Graphical representation of protein abundance ratios in the 
comparison AD vs. ctrl (APOE3/4, BA41/42) before (left) and after applying the filters of at 
least 2 unique peptide IDs and >20% change between AD and control (right). The dotted 
lines indicate a change of 20% up or down (note 4 proteins out of 5678 which have 
abundance ratios higher than 5 are excluded from the graph in panel c). Western blot 
validation from non-demented control (NDC) and AD cases  show examples of a synaptic 
protein that was decreased in the proteomics dataset (SNAP25 d, e, t-test p=0.08), and a glial 
protein that was increased in AD (GFAP, f, g, Mann-Whitney p=0.045).  Data in panels b and 
e are shown as mean and error bars represent the standard error of the mean. Each dot 
represents the value from a single case. Normality of data were assessed with Shapiro-Wilks 
tests.  When comparing the ratio of levels of 9 proteins in AD divided by non-demented 
controls of 9 proteins and comparing these ratios calculated from western blot vs proteomics 
data (h), we observe a significant correlation between ratios measured with the 2 methods 
(Pearson correlation R=0.72, p=0.03), validating the accuracy of our pooled proteomics 
method. Full blots of PSD95, alpha synuclein, tubulin, annexin V, SOD2, and TMEM97 are 
shown in supplemental figure 3. 
 
In silico analysis revealed differences in abundance ratios correlating with increasing 
vulnerability for AD neuropathology 
To determine potential differences in the synaptic proteomes of AD patients vs. control subjects 
dependent on APOE genotype and brain region, we focused on the protein abundance ratios as 
calculated by dividing values from AD patients by matched control subjects, subcategorised 
for APOE3/4 or APOE3/3 genotype, and segregated by brain region (Fig. 3a-c).  More proteins 
were changed in AD patients compared to controls in BA41/42 of APOE4 carriers than any 
other condition (Fig. 3b).  The numbers of protein changes increases progressively from 
APOE3/3 BA17 < APOE3/3 BA41/42 < APOE3/4 BA17 < APOE3/4 BA41/42.  Looking at 
the 15 most upregulated and downregulated pathways detected by Ingenuity Pathway Analysis 
software (Fig. 4) reveals that pathways involved in intracellular signalling, glial proteins 
involved in glia-neuron interactions, and the immune response are upregulated in AD 
compared to control with generally larger effects in the temporal cortex BA41/42.  
Downregulated pathways include many involved in synaptic function such as synaptic long 
term potentiation, glutamate signalling, and calcium signalling. The most downregulated 
pathway in AD APOE3/4 BA/41/42  was oxidative phosphorylation including significant 
downregulation of proteins in complex I, IV, and V. This pathway was  increased in BA17 
indicating a potential compensatory effect in BA17 which has less pathology at end stages of 
disease.  This combination of region specific decreases in synaptic and mitochondrial proteins 
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is very interesting in light of our recent paper showing decreased numbers of mitochondria in 
synaptic terminals in BA41/42 using electron microscopy [40].  All pathways detected with 
IPA analysis are available in supplemental table 3. 
 
Our previous work examining synapses in human post-mortem tissue has revealed that the 
handling of the body and the tissue is critical for maintaining structural and molecular integrity 
of synapses [26, 40].  In particular, we observe that rapid cooling of the body after death 
preserves synapse structure and molecular integrity better even than short post-mortem 
intervals.  Therefore in this study we used samples only from the Edinburgh MRC Sudden 
Death Brain Bank whose robust handling protocol is carried out on each individual ensuring 
that the data is as comparable as possible.  This precluded precise age and sex matching of our 
control groups with our AD groups (see table 1), which could mean that there are confounding 
effects of age and sex on our AD/control comparisons.  However, when we compare BA41/42 
of the AD APOE3/4 to AD APOE3/3 cases, which are better age and sex matched, we observe 
many of the same pathways increased in AD APOE4 carriers compared to AD APOE3 carriers 
as those we observed in the comparison of AD vs control APOE4 carriers (Fig. 4). Less changes 
were observed in BA17 from AD APOE4 carriers compared to AD APOE3 carriers. This 
strongly supports our conclusion that APOE4 influences the synaptic proteome in AD in a 
region-specific manner. Interestingly, in non-demented controls when APOE4 carriers are 
compared to APOE3 carriers in BA41/42, there are changes in the opposite direction to those 
that are observed in APOE4 AD vs control. 
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Fig. 4: Proteins involved in multiple pathways are altered in AD and by APOE genotype 
and brain region. Using Ingenuity Pathway analysis to investigate pathway alterations in the 
1532 proteins that were changed more than 20% in the most vulnerable brain condition 
(APOE3/4 BA41/42) shows that in AD there is a clear upregulation of pathways involved in 
the immune response and cellular signaling and down regulation of several pathways involved 
in synaptic function including long term potentiation, glutamate signaling, and calcium 
ignaling.  These pathways were differentially regulated in the different brain regions and APOE 
genotypes. Comparing APOE4 to APOE3 carriers within the control (con) and AD groups 
similarly reveals region-specific effects of APOE isoform on the synaptic proteome.   Z-scores 
are plotted in d with upregulated proteins shown in red and downregulated in green. 
 
 
To further examine trends in protein changes in an unbiased manner, we performed clustering 
analysis to detect differences in the abundance ratios across these differentially vulnerable 
synaptic populations. Proteins were clustered according to their abundance profile across the 
four calculated ratios (Fig. 5). Each sphere represents an individual protein ID and the distances 
between the spheres indicate the similarity in abundance profile. Different colours are used to 
group proteins together in clusters based on abundance profile similarity. In order to analyse 
the impact/influence of APOE genotype and cortical region, we focused specifically on clusters 
showing a steady increase or decrease in protein abundance across the four groups or only 
demonstrating differences in protein abundance in APOE4 carriers in BA41/42 (Fig. 5). In 
order to determine if these abundance profile specific clusters were associated with specific 
pathways and/or canonical cascades, we have carried out a higher order functional clustering 
analysis using IPA software. IPA pathway analysis and DAVID enrichment analysis 
highlighted multiple affected pathways.  In clusters 4, 5, 8 and 21 which have progressive 
decreases in AD/control ratios as pathological severity increases (Fig 5), we observe pathways 
involved in synaptic function are decreased including glutamate signalling, synaptic long term 
potentiation, GABA receptor signalling, CREB signalling, and synaptic long-term depression. 
Cluster 6 containing proteins that were sharply decreased in the condition with most pathology, 
AD APOE4 BA41/42, similarly showed decreases in pathways involved in synaptic function 
including CREB signalling and GABA receptor signalling, along with decreases in pathways 
implicated in mitochondrial function including oxidative phosphorylation (Fig 5).  
 
Interestingly, when examining clusters 7, 9, and 18 which were progressively increased with 
pathological vulnerability, we observe proteins involved in autophagy and chemokine 
signalling were progressively upregulated in conditions of higher synaptic vulnerability (Fig 
5). Clusters 1 and 2, which included proteins highly upregulated in AD APOE4 BA41/42 
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compared to the other groups indicate increases in pathways involved in actin cytoskeleton 
signalling, NRF2 mediated oxidative stress response, PDGF signalling, and insulin receptor 
signalling, which all implicate non-neuronal contributors to synapse degeneration as has been 
recently emphasised for AD risk by genetic studies [18].  
 
Along with the unbiased bioinformatic analyses, we further interrogated our proteomics dataset 
to examine proteins of interest based on what is known about synapse degeneration in AD from 
model systems.  In addition to loss of proteins involved in synaptic function in remaining 
synapses in AD as shown with bioinformatics, it is likely that there is some degree of synaptic 
remodelling/compensation taking place as some synaptic proteins were increased.  The 
synaptic receptor TMEM97 is increased in remaining synapses in AD vs control APOE4 
carriers in BA41/42 (Fig 3).  This is particularly interesting because TMEM97 is the sigma 2 
receptor, and compounds that disrupt interaction of Ab and sigma 2 receptors are protective in 
mouse models and are being tested for efficacy in human AD as a therapeutic [23].  Clusterin 
is also increased 21% in AD compared to controls.  This is interesting in light of our recent 
work showing clusterin within individual synapses containing amyloid beta in human AD brain 




Fig. 5: Clusters of protein changes. (a) Graphia Professional representation of proteomic 
abundance data across differentially vulnerable synaptic populations. Each sphere represents a 
single protein and the edge represents how similar their abundance trend is towards the other 
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proteins in the dataset. The closer the spheres are the more similar the abundance trend. The 
colours represent the different clusters formed by grouping proteins with similar abundance 
trends. The resulting profiles were grouped into four different categories as shown in the 
example graphical abundance trends for further analysis. The annotation associated with each 
graph represents the cluster numbers which fit each trend and the number of associated 
proteins. Graphs b-e show the top pathway changes in the clusters indicated. 
 
Recent data strongly implicate the complement cascade and microglia in Ab mediated synapse 
loss in mouse models of amyloid deposition [20, 46]. Two studies recently demonstrated 
upregulation of components of the complement system in AD brain and influence of 
complement cascade in synapse dysfunction and loss in a mouse model of tauopathy [12, 31].    
Based on these data, we interrogated our human synaptoneurosome dataset to look at proteins 
important for microglial synapse phagocytosis and specifically the complement system.  
Pathway analysis reveals increases in CD40, IL-6, IL-8, IL-1, IL-2, IL-7 and acute phase 
response  signalling, indicating neuroimmune signalling between neurons and glia in synapses, 
which is modulated by APOE genotype (Fig 4,5).  Further interrogation of the proteomics 
dataset shows increases in C1qA, B, and C in AD brain, which are most pronounced in 
BA41/42 of APOE3 carriers (over 2 fold increases).  We also detect complement components 
C1 and C4 which are increased in most conditions AD brain without a clear effect of APOE 


















Complement C1q subcomponent subunit A 1.77959139 0.69430641 1.0980274 0.93909556 
Complement C1q subcomponent subunit B 1.44369348 0.68392297 0.7091574 0.91265319 
Complement C1q subcomponent subunit C 1.0778657 0.60047611 0.46366574 0.73646894 
Complement C4-A 0.84763652 0.73464438 0.89934544 0.66442196 
Complement C4-B  0.81062454 0.98633814 -0.0877303 0.38715829 
Complement C1s 0.68375909 0.2130724 0.39700963 0.56568522 
Complement component 1 0.29882572 0.59348713 -0.5659684 0.40746573 
Supplemental table 4: Evidence for alterations in proteins involved in the complement 






Of the pathological changes associated with dementia, the best correlate to the extent of 
memory decline in life is the loss of synapses. Synapses are exquisitely complicated structures 
requiring thousands of proteins for the complex process of establishing, maintaining, and 
undergoing synaptic transmission. Work from animal models and human post mortem tissue 
indicates that synapse degeneration is a driving force in disease progression in AD. However, 
to date there has been a lack of data on the precise molecular changes in synapses in human 
AD brain, which impedes the design of hypothesis driven experiments to understand 
mechanisms of synapse degeneration in animal models that are likely to be relevant to human 
disease.  In the literature, we found 20 publications using proteomics on human AD brain tissue 
(supplemental table 1). In proteomics studies examining whole tissue homogenates from AD 
brains without considering APOE genotype, there have been quite varied results.  Three studies 
show decreases in synaptic proteins or pathways involved in synaptic function, which could 
have been explained by synapse loss [1, 38, 59].  To our knowledge only one previous study 
examined the effects of APOE on synaptic proteins [53]. This study used whole tissue 
homogenates from AD and control subjects for proteomics but focused their analysis on a 
group of 191 proteins that had previously been detected in synaptosome fractions of healthy 
subjects.  With this method, they observed a downregulation of glutamate signalling proteins 
and an effect of APOE4 genotype on the abundance of these synaptic proteins.  Our results 
significantly expand upon these findings as we biochemically isolated synaptoneurosomes 
from AD and control subjects and detected over 5,500 proteins, which is over 25 times more 
proteins examined than in the previous study of synaptic proteins.  Synaptoneurosome 
preparations have not previously been used in proteomic studies of AD. Synaptoneurosomes, 
unlike other synaptic fractions, contain both the presynaptic and postsynaptic compartments, 
which is important due to data from model systems implicating both pre and post synapses in 
degenerative mechanisms. Further, the preparation might retain parts of glial processes closely 
associated with the synapse, which is key for understanding the role of non-neuronal cells in 
synapse degeneration, an important topic in the field [18].  
  
We observed that multiple pathways including those associated with synaptic and 
mitochondrial function were downregulated with increasing vulnerability and other pathways 
including intracellular signalling and neuroimmune signalling proteins were increased with 
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increasing vulnerability. This is encouraging as dysfunctional synaptic signalling is consistent 
with multiple lines of evidence from AD animal models[5, 43, 48]. Some of the proteins that 
we observe are reduced in AD synapses have been observed as CSF biomarkers associating 
with disease.  For example, we observe a 25% decrease in neurexin 2 and over 30% decrease 
in neurogranin abundance in  AD APOE4 superior temporal gyrus compared to controls, 
whereas  recently published biomarker studies observed increases in neurexin 2 and 
neurogranin in CSF of people with mild cognitive impairment or AD [14, 29, 41].    In another 
study of CSF, a group of 9 synaptic proteins (GluR2, GluR4, Neuroligin-2, Neurexin-3A, 
Neurexin-2A, Calsynytenin-1, Syntaxin-1B, Thy-1, and VAMP-2)  were increased  [33].  Our 
proteomics data support the notion that proteins may be removed from synapses in AD and at 
least some of these cleared from the brain via CSF. 
 
In addition to the synaptic signalling pathway changes, we observe interesting changes in 
immune-related signals in AD synapses. In recent work examining both iPSCs and human brain 
tissue, APOE4 was strongly associated with reduced expression of regulators of synaptic 
function and increased expression of microglial genes associated with the immune response 
[57].  APOE has been shown to interact with and modulate the immune and inflammatory 
system in the brain especially through its interaction with another important AD genetic risk 
factor TREM2 [4]. Our study also found that proteins involved in the immune system and 
neuroimmune signalling are dysregulated in the AD synapse. Recent evidence has indicated 
that the complement system of innate immunity, particularly complement components C1q and 
C3, are involved in synaptic death in mouse models both downstream of Ab and tau pathology, 
and that ApoE forms a complex with activated C1q which blocks initiation of the complement 
cascade [12, 20, 31, 46, 58]. Our study highlights the importance of these pathways in human 
AD brain and shows that other proteins in this cascade including complement component C4, 
HLA-1, and Clusterin are all increased at the synapse in AD presenting innate immunity as an 
attractive area for further study and therapeutic intervention. Our data indicate that within 
remaining synapses in human AD brain, APOE4 is associated with altered levels of proteins 
involved in synaptic function and proteins involved in the innate immune system. One possible 
interpretation of these data supports the hypothesis that microglia are involved in synaptic 
pruning during disease. 
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Synapses have high energy demands requiring local mitochondrial ATP production.  Both Ab 
and tau have been observed in model systems to impact mitochondrial function and the 
intracellular transport of mitochondria, which impair synaptic function [30, 34, 42]. And there 
is some evidence that APOE4 can impair mitochondria function in cell culture [8]. However, 
the role of APOE4 in synaptic mitochondrial function in human brain has not been studied.  
We observe region and APOE specific changes in proteins involved oxidative phosphorylation 
with a strong decrease in BA41/42 of AD patients that was larger in APOE4 carriers than 
APOE3 carriers.  Conversely, this pathway was  increased in BA17 with the strongest increase 
in E3 carriers.  This could reflect a compensatory increase in mitochondrial function in brain 
regions that are very early in the disease process. Consistent with the BA41/42 data, we recently 
observed a decrease in presynaptic terminals containing multiple mitochondria in the temporal 
cortex of AD patients [40]. 
 
Synaptic degeneration is an important part of AD pathogenesis. Further understanding this 
process and how to delay and/or halt it may lead us towards important novel therapeutic 
targets not only for AD but also for other diseases for which synapse loss is an integral or 
important process. As indicated in Fig 1a and as expected from the literature, APOE4 AD 
cases have a higher degree of amyloid pathology than APOE3 AD cases.  Our data cannot 
disentangle whether APOE4 directly affects the synaptic proteome or does so downstream of 
increasing pathology. We argue that understanding the differences in synaptic proteome in 
AD vs control and APOE4 vs APOE3 will be an important starting point for future 
mechanistic experiments looking for therapeutic interventions.  By coupling subcellular 
fractionation with anatomical knowledge of regional vulnerability and human patient genetics 
we were able to generate the most comprehensive synaptic proteomics profiling datasets from 
human AD patient samples to date. Importantly, we have determined its accuracy through 
experimental validation and links to existing published literature on mechanisms and 
biomarker identification. As an example of the potential utility of such data we were able to 
begin to uncover how AD and APOE4 impact synaptic composition and may be leading to 
synaptic degeneration. Although in this discussion we have highlighted specific proteins and 
cascades correlating with regional vulnerability and discussed their potential roles in disease 
progression and /or regulation this was done to highlight the potential utility of our dataset. 
There are many other potentially important proteins and pathways in these data to explore in 
future studies. We have made the data freely available and hope that this will provide a useful 
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resource for other researchers in the field to use at their discretion. The results described here 
demonstrate that APOE genotype has a profound impact on the molecular fingerprint of the 
synapse and that further understanding of the effects of these protein changes may contribute 
to our understanding of, and ultimately the development of novel therapies for AD.   
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Supplemental Fig 1: Workflow. Samples were prepared from postmortem tissue and 




Supplemental figure 2: Protein degradation blots were completed for all samples using 
NMDA NR2B antibody (a).  The ratio of band 1, which is found in vivo, to band 2, which 
appears with postmoretem degradation was calculated (b) and samples with a ratio <1 were 





Supplementary figure 3: Validation western blots (uncropped) of AD vs non demented 
control (NDC) from BA41/42 of people with APOE3/4 genotype.  Full blots are shown for 
PSD95 and alpha-synuclein (a), SOD2 (b), annexin V (c), TMEM97 (d), beta tubulin (e), and 
total protein at high intensity (f) and low intensity (g). Each of the molecular weight ranges in 
g were quantified for each lane, shown in (h). Comparisons between proteomics and western 
blot data are shown in i. 
 
